QT VASCULAR LTD.
(Company Registration No.: 201305911K)
(Incorporated in Republic of Singapore)
(the "**Company**")

UPDATE TO LITIGATION

*Unless otherwise defined in this announcement, all capitalised terms used herein shall bear the same meanings as ascribed to them in the Company's offer document dated 16 April 2014 (the "**Offer Document**").*

The Board of Directors of the Company would like to provide the following updates to certain ongoing litigations which were disclosed in the Offer Document. As previously disclosed in the Offer Document, AngioScore, Inc. ("**AngioScore**"), an angioplasty company, initiated patent infringement proceedings on 29 June 2012 against the Company's subsidiaries, TriReme Medical, LLC ("**TriReme US**"), Quattro Vascular Pte. Ltd. ("**Quattro Vascular**") and the Company's CEO, Dr Eitan Konstantino ("**Dr. Konstantino**"), relating to the Chocolate PTA (the "**Patent Claim**"). The Patent Claim is currently scheduled for trial in September 2015.

On 27 June 2014, AngioScore added claims under Delaware and California state law (the "State Law Claims"), alleging that Dr. Konstantino breached his fiduciary duties to AngioScore by developing the Chocolate PTA and that TriReme US, Quattro Vascular and the Company aided and abetted the alleged breach. The trial phase for the State Law Claims closed on 21 April 2015 and the trial court requested post-trial briefing prior to rendering its decision.

The Group believes it has meritorious defenses against both the Patent Claim and the State Law Claims (the "Claims"); however, the Company cannot predict the outcome of this litigation. There is also no assurance that the Claims will not reduce the value of, and the market for, the Company's products, thereby materially and adversely affecting the Company's business, financial position, results of operation and prospects.

The Company will update shareholders of the Company as and when there are any material updates to the aforementioned litigation, including its financial effects on the Group.

BY ORDER OF THE BOARD

Mark Allen Wan
Non-Executive Chairman
29 April 2015

The Company was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone +65 6229 8088.